May 22, 2025
Press Releases
Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025
May 22, 2025
Press Releases
Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel Targeted Glue™ degraders at SLAS Europe 2025
March 20, 2025
Press Releases
Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences
January 13, 2025
Press Releases
Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer
September 3, 2024
Press Releases
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the clinic and building a robust pipeline
May 23, 2024
Press Releases
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
January 24, 2024
Press Releases
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders